{
    "info": {
        "nct_id": "NCT04692493",
        "official_title": "A Real-World Comparative Effectiveness Trial of Treatment Strategies in Patients With Rheumatoid Arthritis: The RA-PRO Pragmatic Trial (RA-PROPR)",
        "inclusion_criteria": "1. Patients with active, disabling RA (CDAI ≥10 and HAQ ≥0.5) despite the use/experience for ≥ 3 months of a TNFi-biologic OR discontinued the medication(s) due to intolerability or toxicity irrespective of treatment duration prior to the first dose of study drug ;\n2. If receiving glucocorticoids (≤10 mg/day of prednisone of equivalent) or NSAIDs, on stable doses for ≥2 weeks prior to randomization; and\n3. Insurance plan or patient assistance program allows access to at least 1 drug in each of the two treatment strategies, TNFi-biologic vs. tsDMARD.\n\nParticipants will be allowed to continue their conventional synthetic DMARD (csDMARD) therapy if they had been using it for ≥ 3 months and on a stable dose for ≥ 4 weeks prior to the first dose of study drug. The following csDMARDs are allowed: methotrexate (MTX), sulfasalazine, hydroxychloroquine, and leflunomide (TNFi-biologic and tsDMARD) through insurance plan or a patient assistance program/plan.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "1. Prior treatment with more than three biologics, defined as TNFi-biologic or non-TNFi biologic\n2. Prior treatment with targeted synthetic DMARD\n3. Concomitant use of leflunomide, sulfasalazine, cyclosporine, or azathioprine within 2-months before randomization;\n4. History of sensitivity to all 4 non-TNF-biologic or a targeted synthetic DMARD;\n5. Glucocorticoid injection (intravenous, intramuscular, or intraarticular) within 1 month of study entry;\n6. Live vaccine within 90 days of study entry;\n7. Acute or chronic infections with parenteral antibiotics or hospitalization (including tuberculosis, bacterial sepsis; invasive fungal infections (such as histoplasmosis)) within 1 month or oral antibiotics within 2 weeks of study entry;\n8. History of HIV or any opportunistic infection;\n9. New York Heart Association Class III or IV heart failure;\n10. Latent TB for which anti-tubercular treatment has not been started;\n11. Untreated Hepatitis B or C infection;\n12. History of deep venous thrombosis or pulmonary embolism; or\n13. Pregnant or nursing women; or\n14. History of herpes zoster or shingles.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "1. Patients with active, disabling RA (CDAI ≥10 and HAQ ≥0.5) despite the use/experience for ≥ 3 months of a TNFi-biologic OR discontinued the medication(s) due to intolerability or toxicity irrespective of treatment duration prior to the first dose of study drug ;",
            "criterions": [
                {
                    "exact_snippets": "active, disabling RA",
                    "criterion": "rheumatoid arthritis (RA)",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "disabling"
                        }
                    ]
                },
                {
                    "exact_snippets": "CDAI ≥10",
                    "criterion": "Clinical Disease Activity Index (CDAI)",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": ""
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "HAQ ≥0.5",
                    "criterion": "Health Assessment Questionnaire (HAQ) score",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 0.5,
                                "unit": ""
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "despite the use/experience for ≥ 3 months of a TNFi-biologic",
                    "criterion": "TNFi-biologic use",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "OR discontinued the medication(s) due to intolerability or toxicity",
                    "criterion": "TNFi-biologic discontinuation",
                    "requirements": [
                        {
                            "requirement_type": "discontinuation_reason",
                            "expected_value": [
                                "intolerability",
                                "toxicity"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. If receiving glucocorticoids (≤10 mg/day of prednisone of equivalent) or NSAIDs, on stable doses for ≥2 weeks prior to randomization; and",
            "criterions": [
                {
                    "exact_snippets": "receiving glucocorticoids (≤10 mg/day of prednisone of equivalent)",
                    "criterion": "glucocorticoid use",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 10,
                                "unit": "mg/day of prednisone or equivalent"
                            }
                        },
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "on stable doses for ≥2 weeks prior to randomization",
                    "criterion": "medication dose stability",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "status",
                            "expected_value": "stable"
                        }
                    ]
                },
                {
                    "exact_snippets": "receiving ... NSAIDs",
                    "criterion": "NSAID use",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "on stable doses for ≥2 weeks prior to randomization",
                    "criterion": "NSAID dose stability",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "status",
                            "expected_value": "stable"
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Insurance plan or patient assistance program allows access to at least 1 drug in each of the two treatment strategies, TNFi-biologic vs. tsDMARD.",
            "criterions": [
                {
                    "exact_snippets": "Insurance plan or patient assistance program allows access to at least 1 drug in each of the two treatment strategies, TNFi-biologic vs. tsDMARD.",
                    "criterion": "insurance or patient assistance program drug access",
                    "requirements": [
                        {
                            "requirement_type": "access to at least 1 drug in TNFi-biologic treatment strategy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "drug"
                            }
                        },
                        {
                            "requirement_type": "access to at least 1 drug in tsDMARD treatment strategy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "drug"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Participants will be allowed to continue their conventional synthetic DMARD (csDMARD) therapy if they had been using it for ≥ 3 months and on a stable dose for ≥ 4 weeks prior to the first dose of study drug. The following csDMARDs are allowed: methotrexate (MTX), sulfasalazine, hydroxychloroquine, and leflunomide (TNFi-biologic and tsDMARD) through insurance plan or a patient assistance program/plan.",
            "criterions": [
                {
                    "exact_snippets": "using it for ≥ 3 months",
                    "criterion": "csDMARD therapy duration",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "on a stable dose for ≥ 4 weeks prior to the first dose of study drug",
                    "criterion": "csDMARD therapy dose stability",
                    "requirements": [
                        {
                            "requirement_type": "stable dose duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "The following csDMARDs are allowed: methotrexate (MTX), sulfasalazine, hydroxychloroquine, and leflunomide",
                    "criterion": "csDMARD type",
                    "requirements": [
                        {
                            "requirement_type": "allowed agents",
                            "expected_value": [
                                "methotrexate (MTX)",
                                "sulfasalazine",
                                "hydroxychloroquine",
                                "leflunomide"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "10. Latent TB for which anti-tubercular treatment has not been started;",
            "criterions": [
                {
                    "exact_snippets": "Latent TB for which anti-tubercular treatment has not been started",
                    "criterion": "latent tuberculosis infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "anti-tubercular treatment not started"
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. History of deep venous thrombosis or pulmonary embolism; or",
            "criterions": [
                {
                    "exact_snippets": "History of deep venous thrombosis",
                    "criterion": "deep venous thrombosis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... pulmonary embolism",
                    "criterion": "pulmonary embolism",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "14. History of herpes zoster or shingles.",
            "criterions": [
                {
                    "exact_snippets": "History of herpes zoster or shingles.",
                    "criterion": "herpes zoster or shingles",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. History of sensitivity to all 4 non-TNF-biologic or a targeted synthetic DMARD;",
            "criterions": [
                {
                    "exact_snippets": "History of sensitivity to all 4 non-TNF-biologic or a targeted synthetic DMARD",
                    "criterion": "sensitivity to non-TNF-biologic DMARDs",
                    "requirements": [
                        {
                            "requirement_type": "history of sensitivity",
                            "expected_value": "all 4 non-TNF-biologic DMARDs"
                        }
                    ]
                },
                {
                    "exact_snippets": "History of sensitivity to ... a targeted synthetic DMARD",
                    "criterion": "sensitivity to targeted synthetic DMARD",
                    "requirements": [
                        {
                            "requirement_type": "history of sensitivity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Live vaccine within 90 days of study entry;",
            "criterions": [
                {
                    "exact_snippets": "Live vaccine within 90 days of study entry",
                    "criterion": "live vaccine administration",
                    "requirements": [
                        {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 90,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "13. Pregnant or nursing women; or",
            "criterions": [
                {
                    "exact_snippets": "Pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "nursing women",
                    "criterion": "nursing status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Prior treatment with more than three biologics, defined as TNFi-biologic or non-TNFi biologic",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with more than three biologics, defined as TNFi-biologic or non-TNFi biologic",
                    "criterion": "prior biologic treatment",
                    "requirements": [
                        {
                            "requirement_type": "number of prior biologics",
                            "expected_value": {
                                "operator": ">",
                                "value": 3,
                                "unit": "biologics"
                            }
                        },
                        {
                            "requirement_type": "type of biologics",
                            "expected_value": [
                                "TNFi-biologic",
                                "non-TNFi biologic"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Concomitant use of leflunomide, sulfasalazine, cyclosporine, or azathioprine within 2-months before randomization;",
            "criterions": [
                {
                    "exact_snippets": "Concomitant use of leflunomide, sulfasalazine, cyclosporine, or azathioprine within 2-months before randomization",
                    "criterion": "concomitant use of leflunomide, sulfasalazine, cyclosporine, or azathioprine",
                    "requirements": [
                        {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "months before randomization"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Prior treatment with targeted synthetic DMARD",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with targeted synthetic DMARD",
                    "criterion": "prior treatment with targeted synthetic DMARD",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. New York Heart Association Class III or IV heart failure;",
            "criterions": [
                {
                    "exact_snippets": "New York Heart Association Class III or IV heart failure",
                    "criterion": "heart failure (New York Heart Association class)",
                    "requirements": [
                        {
                            "requirement_type": "class",
                            "expected_value": [
                                "III",
                                "IV"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. History of HIV or any opportunistic infection;",
            "criterions": [
                {
                    "exact_snippets": "History of HIV",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "any opportunistic infection",
                    "criterion": "opportunistic infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Glucocorticoid injection (intravenous, intramuscular, or intraarticular) within 1 month of study entry;",
            "criterions": [
                {
                    "exact_snippets": "Glucocorticoid injection (intravenous, intramuscular, or intraarticular) within 1 month of study entry",
                    "criterion": "glucocorticoid injection",
                    "requirements": [
                        {
                            "requirement_type": "route",
                            "expected_value": [
                                "intravenous",
                                "intramuscular",
                                "intraarticular"
                            ]
                        },
                        {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "month"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Acute or chronic infections with parenteral antibiotics or hospitalization (including tuberculosis, bacterial sepsis; invasive fungal infections (such as histoplasmosis)) within 1 month or oral antibiotics within 2 weeks of study entry;",
            "criterions": [
                {
                    "exact_snippets": "Acute or chronic infections with parenteral antibiotics or hospitalization ... within 1 month",
                    "criterion": "acute or chronic infections requiring parenteral antibiotics or hospitalization",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "month"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "tuberculosis, bacterial sepsis; invasive fungal infections (such as histoplasmosis) ... within 1 month",
                    "criterion": "tuberculosis, bacterial sepsis, or invasive fungal infections (such as histoplasmosis)",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "month"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "oral antibiotics within 2 weeks of study entry",
                    "criterion": "use of oral antibiotics",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Untreated Hepatitis B or C infection;",
            "criterions": [
                {
                    "exact_snippets": "Untreated Hepatitis B or C infection",
                    "criterion": "Hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "untreated"
                        }
                    ]
                },
                {
                    "exact_snippets": "Untreated Hepatitis B or C infection",
                    "criterion": "Hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "untreated"
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}